2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update)

Catheterization and Cardiovascular Interventions

Volumn 74, Issue 7, 2009, Pages

  Kushner, Frederick G ^a   Hand, Mary ^a   Smith Jr , Sidney C ^a   King III, Spencer B ^a   Anderson, Jeffrey L ^a   Antman, Elliott M ^a   Bailey, Steven R ^a   Bates, Eric R ^a   Blankenship, James C ^a   Casey Jr , Donald E ^a   Green, Lee A ^a   Hochman, Judith S ^a   Jacobs, Alice K ^a   Krumholz, Harlan M ^a   Morrison, Douglass A ^a   Ornato, Joseph P ^a   Pearle, David L ^a   Peterson, Eric D ^a   Sloan, Michael A ^a   Whitlow, Patrick L ^a   Williams, David O ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMERICAN HEART ASSOCIATION; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; BLOOD GLUCOSE; CORONARY ANGIOGRAPHY; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; MYOCARDIAL INFARCTION; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; STENTS; THROMBECTOMY; TIME FACTORS; TRIAGE; UNITED STATES;

EID: 72549105332     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22351     Document Type: Review

References (162)

1. ACCF/AHA Task Force on Practice Guidelines. Methodologies and Policies from the ACCF/AHA Task Force on Practice Guidelines. Available at: http://www.acc.org/qualityandscience/clinical/manual/ pdfs/methodology.pdf; Accessed August 1, 2009.
2. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;47:e1-121.
3. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol. 2004;44:e1-e211.
4. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. J Am Coll Cardiol. 2008;51:210-247
5. King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2008;51:172-209.
6. Gurm H, Tamhane U, Meier P, et al. A comparison of abciximab and small molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials. Circ Cardiovasc Intervent. 2009;2:230-236
7. De Luca G, Ucci G, Cassetti E, et al. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol. 2009;53:1668-1673
8. Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358:2205-2217 (Pubitemid 351724450)
9. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-2230 (Pubitemid 351724451)
10. Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation. 2009;119:1933-1940
11. Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA. 2008;299:1788-1799 (Pubitemid 351549970)
12. Van't Hof AW, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, doubleblind, randomised controlled trial. Lancet. 2008;372:537-546
13. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373:723-731
14. Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360:2705-2718
15. Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet. 2008;371:559-568 (Pubitemid 351232030)
16. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283-1297
17. Svilaas T, Vlaar PJ, van der Horst I, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358:557-567 (Pubitemid 351214283)
18. Sardella G, Mancone M, Bucciarelli-Ducci C, et al. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol. 2009;53:309-315
19. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007;115: 3189-3196 (Pubitemid 47012233)
20. Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213-224
21. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961-972
22. Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009;360:2176-2190
23. Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360:2165-2175
24. Wagner GS, Macfarlane P, Wellens H, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part VI: acute ischemia/infarction: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. J Am Coll Cardiol. 2009;53:1003-1011
25. Hamm C. ON-TIME-2. Ongoing-Tirofiban In Myocardial Infarction evaluation 1 year follow-up. Available at: www. clinicaltrialresults.org/slides/OnTime2- Orlando.ppt.; Accessed March 30, 2009.
26. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152:627-635
27. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrelin patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015 (Pubitemid 350106708)
28. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association,American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Dent Assoc. 2007;138:652-655
29. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platele tinhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111:2560-2564 (Pubitemid 40740853)
30. Plavix (clopidogrel bisulfate) [package insert]. Bridgewater, NJ:Bristol-Myers Squibb Sanofi-aventis. Sanofi-aventis, 2009.
31. Kim JH, Newby LK, Clare RM, et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J. 2008;156:886-892
32. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944
33. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713-718
34. Stanek E. Medco study: PPIs reduce clopidogrel efficacy post-stenting. Available at: http://cardiobrief.org/2009/05/06/scai-clopidogrelppi-wed-1130am/. Accessed July 29, 2009.
35. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989-997
36. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008;51:1404-1411
37. Prasugrel [drug label]. Indianapolis, Ind: Eli Lilly and Co., 2009.
38. Wrishko RE, Ernest CS, Small DS, et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol. 2009;49:984-998
39. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation. 2004;110:e489-93.
40. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised,double-blind, placebo-controlled trial. Lancet. 2004;364:331-337
41. Jneid H, Bhatt DL, Corti R, et al. Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch Intern Med. 2003;163:1145-1153 (Pubitemid 36613066)
42. Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thien opyridinesin vascular disease. Eur Heart J. 2000;21:2033-2041. (Pubitemid 32006217)
43. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533 (Pubitemid 32772726)
44. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke. 2006;37:577-617.
45. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-1988 (Pubitemid 46694290)
46. Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:699-700.
47. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373:309-317
48. Roden DM, Stein C. Clopidogrel and the concept of high-risk pharmacokinetics. Circulation. 2009;119:2127-2130
49. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30:916-922
50. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375
51. Mega J, Thakuria JV, Cannon CP, Sabatine MS. Sequence variations in CYP metabolism genes and cardiovascular outcomes following treatment with clopidogrel: insights from the CLARITY-TIMI 28 genomic study. Available at: http://content.onlinejacc.org/cgi/reprint/51/10-Suppl-A/A178.pdf. Accessed May 25, 2009.
52. Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P4502C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009;103:806-811
53. Mega J, Close S, Wiviott S, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362
54. Aspirin for the prevention of cardiovascular disease. Available at: http://www.pharmacistsletter.com/(S(ea4ssifcnuy01j45v2l24zqc))/pl/ detaildocuments/250601.pdf?cs=&s=PL. Accessed May 26, 2009.
55. Michelson AD, Frelinger AL III, Braunwald E, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009;30:1753-1763
56. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmaco dynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48:475-484
57. Price MJ, Berger PB, Angiolillo DJ, et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITA Strial. Am Heart J. 2009;157:818-824
58. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189 (Pubitemid 40397259)
59. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52:1502-1517
60. Aubert RE, Epstein RS, Teagarden JR, et al. Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study. Circulation. 2008;118:S-815. Abstract.
61. Dunn SP, Macaulay TE, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation. 2008;118:S-815. Abstract.
62. Ramirez JF, Selzer F, Chakaprani R. Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcome safter PCI: the NHLBI Dynamic Registry. J Am Coll Cardiol. 2009;53:A27-A28. Abstract.
63. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256-260
64. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101:714-719
65. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923-2932 (Pubitemid 350291199)
66. U.S. Food and Drug Administration. Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm. Accessed November 17, 2009.
67. Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:119-125
68. Mehran R, Brodie B, Cox DA, et al. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J. 2008;156:44-56. (Pubitemid 351862292)
69. Dangas GD, Lansky AJ, Brodie BR. Predictors of Stent Thrombosis After Primary Angioplasty in Acute Myocardial Infarction: The HORIZONS-AMI Trial. Available at: http://www.cardiosource.com/rapidnewssummaries/summary.asp?SumID= 406. Accessed August 3, 2009.
70. ASSENT-4 PCI Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial.Lancet. 2006;367:569-578
71. Ellis SG, Armstrong P, Betriu A, et al. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: designand rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J. 2004;147:E16.72 Deleted in proof.
72. Alp NJ, Gershlick AH, Carver A, et al. Rescue angioplasty for failed thrombolysis in older patients: insights from the REACT trial. Int J Cardiol. 2008;125:254-257
73. Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med. 2005;353:2758-2768 (Pubitemid 43016815)
74. Collet JP, Montalescot G, Le May M, et al. Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. J Am Coll Cardiol. 2006;48:1326-1335 (Pubitemid 44436802)
75. Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, et al. Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction: a meta-analysis of randomized trials. J Am Coll Cardiol. 2007;49:422-430 (Pubitemid 46156979)
76. Lincoff AM, Califf RM, Van de Werf F, et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA. 2002;288:2130-2135
77. Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation. 2006;114:2019-2025
78. Antman E. Time is muscle: translation into practice. J Am Coll Cardiol. 2008;52:1216-1221
79. Rathore SS, Curtis JP, Chen J, et al. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. BMJ. 2009;338:b1807.
80. Armstrong PW, Westerhout CM, Welsh R. Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardialinfarction. Circulation. 2009;119:1293-1303
81. Jacobs AK, Antman EM, Faxon DP, et al. Development of systems of care for ST-elevation myocardial infarction patients: executive summary. Circulation. 2007;116:217-230
82. Jacobs AK. Regional systems of care for patients with ST-elevation myocardial infarction: being at the right place at the right time. Circulation. 2007;116:689-692 (Pubitemid 47255984)
83. Bonow RO, Masoudi FA, Rumsfeld JS, et al. ACC/AHA classification of care metrics: performance measures and quality metrics: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2008;52:2113-2117
84. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 performance measures for adults with ST-elevation and non-STelevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction). Circulation. 2008;118:2596-2648
85. American Heart Association. Get With The Guidelines. Available at: http://www.americanheart.org/presenter.jhtml?identifier=1165. Accessed June 10, 2009.
86. Measure Comparison (Inpatient Hospital Quality Measures). Available at: http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename= QnetPublic%2FPage%2FQnetTier3&cid-1138900297065. Accessed June 10, 2009.
87. National Cardiovascular Data Registry. Action Registry-GWTG. Available at: http://www.ncdr.com/webncdr/ACTION/Default.aspx. Accessed June 10, 2009.
88. The Joint Commission. Acute Myocardial Infarction Core Measure Set. Available at: http://www.jointcommission.org/ Performance Measurement/ PerformanceMeasurement/AcuteMyocardialInfarctionCoreMeasureSet.htm. Accessed June 10, 2009.
89. American Heart Association. Mission: lifeline. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3050213. Accessed June 10, 2009.
90. Henry TD, Sharkey SW, Burke MN, et al. A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation. 2007;116:721-728 (Pubitemid 47255989)
91. Le May MR, So DY, Dionne R, et al. A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2008;358:231-240
92. Ting HH, Rihal CS, Gersh BJ, et al. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation. 2007;116:729-736
93. Kosiborod M, Inzucchi SE, Goyal A, et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA. 2009;301:1556-1564
94. Malmberg K, Norhammar A, Wedel H, et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction:long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999;99:2626-2632 (Pubitemid 29237448)
95. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-461 (Pubitemid 43200296)
96. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-STelevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction). J Am Coll Cardiol. 2007;50:e1-157.
97. Wiener RS, Wiener DC, Larson R. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA. 2008;300:933-944
98. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119-1131
99. Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Anesthesiology. 2008;109:14-24.
100. Marfella R, Di Filippo C, Portoghese M, et al. Tight glycemic controlreduces heart inflammation and remodeling during acute myocardial infarction in hyperglycemic patients. J Am Coll Cardiol. 2009;53:1425-1436
101. Vlaar PJ, Svilaas T, van der Horst I, et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet. 2008;371:1915-1920 (Pubitemid 351778190)
102. Bavry AA, Kumbhani DJ, Bhatt D. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. Eur Heart J. 2008;29:2989-3001.
103. Burzotta F, De Vita M, Gu YL, et al. Clinical impact of thrombectomyin acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. Eur Heart J. 2009;30:2193-2203
104. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. 2009;360:1946-1959
105. Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment ('cooling-off' strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA. 2003;290:1593-1599 (Pubitemid 37441261)
106. Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med. 2008;358:342-352 (Pubitemid 351159233)
107. Garg P, Normand SL, Silbaugh TS, et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation. 2008;118:2277-2285
108. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231 (Pubitemid 38067635)
109. Keeley EC, Boura JA, Grines C. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20. (Pubitemid 36050955)
110. Zhu MM, Feit A, Chadow H, et al. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol. 2001;88:297-301. (Pubitemid 32721960)
111. Nordmann AJ, Hengstler P, Harr T, et al. Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials. Am J Med. 2004;116:253-262 (Pubitemid 38224233)
112. Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med. 2008;359:1330-1342
113. Hannan EL, Racz M, Walford G, et al. Drug-eluting versus bare-metalstents in the treatment of patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2008;1:129-135
114. Pasceri V, Patti G, Speciale G, et al. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J. 2007;153:749-754 (Pubitemid 46602146)
115. Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007;28:2706-2713 (Pubitemid 350139205)
116. De Luca G, Stone GW, Suryapranata H, et al. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Int J Cardiol. 2009;133:213-222
117. Van de Werf F. Drug-eluting stents in acute myocardial infarction. N Engl J Med. 2006;355:1169-1170 (Pubitemid 43315479)
118. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol. 2006;48:924-930
119. McCullough PA, Bertrand ME, Brinker JA, et al. A meta-analysis of therenal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006;48:692-699
120. Kuhn MJ, Chen N, Sahani DV, et al. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. AJR Am J Roentgenol. 2008;191:151-157 (Pubitemid 351955220)
121. Rudnick MR, Davidson C, Laskey W, et al. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. Am Heart J. 2008;156:776-782
122. Thomsen HS, Morcos SK, Erley CM, et al. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol. 2008;43:170-178
123. Reed M, Meier P, Tamhane UU, et al. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv. 2009;2:645-654
124. Heinrich MC, Haberle L, Muller V, et al. Nephrotoxicity of iso-osmolariodixanol compared with nonionic low-osmolar contrast media: meta analysis of randomized controlled trials. Radiology. 2009;250:68-86.
125. Bech GJ, De Bruyne B, Bonnier HJ, et al. Long-term followup after deferral of percutaneous transluminal coronary angioplasty of intermediat estenosis on the basis of coronary pressure measurement. J Am Coll Cardiol. 1998;31:841-847 (Pubitemid 28186421)
126. Berger A, Botman KJ, MacCarthy PA, et al. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. J Am Coll Cardiol. 2005;46:438-442 (Pubitemid 41040283)
127. Botman KJ, Pijls NH, Bech JW, et al. Percutaneous coronary intervention or bypass surgery in multivessel disease? A tailored approach based on coronary pressure measurement. Catheter Cardiovasc Interv. 2004;63:184-191
128. Caymaz O, Fak AS, Tezcan H, et al. Correlation of myocardial fractional flow reserve with thallium-201 SPECT imaging in intermediate severity coronary artery lesions. J Invasive Cardiol. 2000;12:345-350
129. Chamuleau SA, Meuwissen M, Koch KT, et al. Usefulness of fractional flow reserve for risk stratification of patients with multivessel coronary artery disease and an intermediate stenosis. Am J Cardiol. 2002;89:377-380 (Pubitemid 34144602)
130. Christou MA, Siontis GC, Katritsis DG, et al. Meta-analysis of fractional flow reserve versus quantitative coronary angiography and noninvasive imaging for evaluation of myocardial ischemia. Am J Cardiol. 2007;99:450-456 (Pubitemid 46215544)
131. Costa MA, Sabate M, Staico R, et al. Anatomical and physiologic assessments in patients with small coronary artery disease: final results of the Physiologic and Anatomical Evaluation Prior to and After Stent Implantation in Small Coronary Vessels (PHANTOM) trial. Am Heart J. 2007;153:296-297
132. Courtis J, Rodes-Cabau J, Larose E, et al. Comparison of medical treatment and coronary revascularization in patients with moderatecoronary lesions and borderline fractional flow reserve measurements. Catheter Cardiovasc Interv. 2008;71:541-548
133. Pijls NH, De Bruyne B, Peels K, et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med. 1996;334:1703-1708 (Pubitemid 26193622)
134. Verna E, Lattanzio M, Ghiringhelli S, et al. Performing versus deferring coronary angioplasty based on functional evaluation of vessel stenosis by pressure measurements: a clinical outcome study. J Cardiovasc Med(Hagerstown). 2006;7:169-175 (Pubitemid 44152935)
135. Yanagisawa H, Chikamori T, Tanaka N, et al. Correlation between thallium-201 myocardial perfusion defects and the functional severity of coronary artery stenosis as assessed by pressure-derived myocardial fractional flow reserve. Circ J. 2002;66:1105-1109 (Pubitemid 35416315)
136. Yanagisawa H, Chikamori T, Tanaka N, et al. Application of pressure derived myocardial fractional flow reserve in assessing the functional severity of coronary artery stenosis in patients with diabetes mellitus. Circ J. 2004;68:993-998 (Pubitemid 39540127)
137. Park SJ, Hong MK, Lee CW, et al. Elective stenting of unprotected leftmain coronary artery stenosis: effect of debulking before stenting and intravascular ultrasound guidance. J Am Coll Cardiol. 2001;38:1054-1060
138. Seung KB, Park DW, Kim YH, et al. Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med. 2008;358:1781-1792 (Pubitemid 351581190)
139. Chieffo A, Stankovic G, Bonizzoni E, et al. Early and midterm results of drug-eluting stent implantation in unprotected left main. Circulation. 2005;111:791-795 (Pubitemid 40250640)
140. Chieffo A, Morici N, Maisano F, et al. Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience. Circulation. 2006;113:2542-2547 (Pubitemid 43948033)
141. Chieffo A, Park SJ, Valgimigli M, et al. Favorable long-term outcome after drug-eluting stent implantation in non-bifurcation lesions that involve unprotected left main coronary artery: a multicenter registry. Circulation. 2007;116:158-162 (Pubitemid 47057521)
142. Kim YH, Dangas GD, Solinas E, et al. Effectiveness of drug-eluting stent implantation for patients with unprotected left main coronary artery stenosis. Am J Cardiol. 2008;101:801-806
143. Takagi T, Stankovic G, Finci L, et al. Results and long-term predictors of adverse clinical events after elective percutaneous interventions on unprotected left main coronary artery. Circulation. 2002;106:698-702. (Pubitemid 34851929)
144. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003;41:159-168
145. Huang HW, Brent BN, Shaw R. Trends in percutaneous versus surgical revascularization of unprotected left main coronary stenosis in the drug eluting stent era: a report from the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR). Catheter Cardiovasc Interv. 2006;68:867-872 (Pubitemid 44847091)
146. Baim DS, Mauri L, Cutlip DC. Drug-eluting stenting for unprotected left main coronary artery disease: are we ready to replace bypass surgery. J Am Coll Cardiol? 2006;47:878-881 (Pubitemid 43243115)
147. Brinker. The left main facts: faced, spun, but alas too few. J Am Coll Cardiol. 2008;51:893-898
148. Taggart DP, Kaul S, Boden WE, et al. Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. J Am Coll Cardiol. 2008;51:885-892 (Pubitemid 351291667)
149. Buszman PE, Kiesz SR, Bochenek A, et al. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol. 2008;51:538-545 (Pubitemid 351146684)
150. Lee MS, Kapoor N, Jamal F, et al. Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol. 2006;47:864-870 (Pubitemid 43243113)
151. Palmerini T, Marzocchi A, Marrozzini C, et al. Comparison between coronary angioplasty and coronary artery bypass surgery for the treatment of unprotected left main coronary artery stenosis (the Bologna Registry). Am J Cardiol. 2006;98:54-59 (Pubitemid 43902697)
152. Rodes-Cabau J, Deblois J, Bertrand OF, et al. Nonrandomized comparison of coronary artery bypass surgery and percutaneous coronary intervention for the treatment of unprotected left main coronary artery disease in octogenarians. Circulation. 2008;118:2374-2381
153. Sanmartin M, Baz JA, Claro R, et al. Comparison of drug-eluting stents versus surgery for unprotected left main coronary artery disease. Am J Cardiol. 2007;100:970-973 (Pubitemid 47371225)
154. White A, Kedia G, Mirocha J, et al. Comparison of coronary artery bypass surgery and percutaneous drug-eluting stent implantation for treatment of left main coronary artery stenosis. JACC Cardiovasc Interv. 2008;1:236-245 (Pubitemid 351816792)
155. Brener SJ, Galla JM, Bryant R III, et al. Comparison of percutaneous versus surgical revascularization of severe unprotected left main coronary stenosis in matched patients. Am J Cardiol. 2008;101:169-172
156. Kereiakes DJ, Faxon D. Left main coronary revascularization at the cross roads. Circulation. 2006;113:2480-2484 (Pubitemid 43948025)
157. Yusuf S, Zhao F,Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502. (Pubitemid 32758501)
158. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420 (Pubitemid 35340537)
159. Montalescot G. Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Randomized for an immediate or Delayed intervention. Available at: http://www.theheart.org/article/954535.do. Accessed August 3, 2009.
160. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA. 2007;297:591-602.
161. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189-198 (Pubitemid 34113814)
162. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598-1660